Shareholders Approve Reverse Stock Split Authority to Address Nasdaq Delisting Threat
MDCX sits 37% above its 52-week low of $0.25 on light trading volume (0.3× avg).
Summary
Medicus Pharma shareholders approved a resolution authorizing the Board to implement a reverse stock split up to 1:50, a crucial step to meet Nasdaq's minimum bid price requirement and avoid delisting.
Key Events · Corporate Governance and Compliance · MDCX
-
Reverse Stock Split Authority Approved
Shareholders approved a special resolution granting the Board discretion to effect a common share consolidation (reverse stock split) at a ratio up to 1:50. This authority is critical for the company to meet Nasdaq's minimum bid price requirement.
-
Auditors Ratified
Shareholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the 2026 fiscal year.
-
Directors Elected
All nine nominated directors were elected to serve one-year terms until the 2027 annual meeting.
Analysis · MDCX · Life Sciences
Shareholders have granted the Board discretion to execute a reverse stock split up to a 1:50 ratio. This is a critical development for Medicus Pharma, which previously received a Nasdaq delisting notice for failing to meet the minimum bid price. The reverse split is a necessary step to increase the per-share price and comply with Nasdaq's listing requirements, potentially preventing a delisting that would severely impact the company's ability to raise capital and investor confidence, especially given its ongoing financial distress and going concern warnings.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDCX was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.2M. The 52-week trading range was $0.25 to $3.69. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.